Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + formoterol fumarate
- Development stage
- Unknown
- Lead developer
- SkyePharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Abriff is a pressurised metered-dose inhaler containing the fixed-dose combination of fluticasone propionate and formoterol fumarate dihydrate for regular maintenance treatment of asthma when an inhaled corticosteroid plus a long-acting beta-2 adrenergic agonist is appropriate. Fluticasone propionate is an inhaled glucocorticoid that suppresses airway inflammation, while formoterol is a long-acting beta-2 adrenergic agonist that relaxes bronchial smooth muscle to improve airflow. Abriff is marketed by Mundipharma; the Italian product information lists pressurised inhalation-suspension strengths of 125 micrograms/5 micrograms and 250 micrograms/10 micrograms per actuation. ([api.aifa.gov.it](https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/organizzazione/2600/farmaci/42292/stampati?ts=RCP))
- Brand names
- AbriffAbriff K-HalerAfferaAffera K-HalerFlutiformFlutiform K-HalerFlutiformoIffeza
- Other names
- fluticasone propionate/formoterol fumarate dihydrate
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on fluticasone propionate + formoterol fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + formoterol fumarate.